215 related articles for article (PubMed ID: 28881752)
1. Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma.
Li H; Wang X; Fang Y; Huo Z; Lu X; Zhan X; Deng X; Peng C; Shen B
Oncotarget; 2017 Aug; 8(32):52571-52583. PubMed ID: 28881752
[TBL] [Abstract][Full Text] [Related]
2. Integrated transcriptome meta-analysis of pancreatic ductal adenocarcinoma and matched adjacent pancreatic tissues.
Atay S
PeerJ; 2020; 8():e10141. PubMed ID: 33194391
[TBL] [Abstract][Full Text] [Related]
3. Candidate agents for pancreatic ductal adenocarcinoma identified by a sub-pathway based method.
Lin Y; Jin Y; Lin LJ; Cao Y; Zhang Y; Chen SF; Zheng CQ
Gene; 2014 May; 540(2):232-7. PubMed ID: 24561286
[TBL] [Abstract][Full Text] [Related]
4. Four potential microRNAs affect the progression of pancreatic ductal adenocarcinoma by targeting MET via the PI3K/AKT signaling pathway.
Yao LC; Jiang XH; Yan SS; Wang W; Wu L; Zhai LL; Xiang F; Ji T; Ye L; Tang ZG
Oncol Lett; 2021 Apr; 21(4):326. PubMed ID: 33692858
[TBL] [Abstract][Full Text] [Related]
5. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
6. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of abnormal expression, prognostic value and oncogenic role of the hub gene FN1 in pancreatic ductal adenocarcinoma
Lei X; Chen G; Li J; Wen W; Gong J; Fu J
PeerJ; 2021; 9():e12141. PubMed ID: 34567847
[TBL] [Abstract][Full Text] [Related]
8. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
[TBL] [Abstract][Full Text] [Related]
9. EFNB2 acts as the target of miR-557 to facilitate cell proliferation, migration and invasion in pancreatic ductal adenocarcinoma by bioinformatics analysis and verification.
Zhang Y; Zhang R; Ding X; Ai K
Am J Transl Res; 2018; 10(11):3514-3528. PubMed ID: 30662604
[TBL] [Abstract][Full Text] [Related]
10. Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma.
Chung JC; Oh MJ; Choi SH; Bae CD
ANZ J Surg; 2008 Apr; 78(4):245-51. PubMed ID: 18366394
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugs.
Zhao B; Qin C; Li Z; Wang Y; Li T; Cao H; Yang X; Li T; Wang W
Cancer Cell Int; 2022 Dec; 22(1):374. PubMed ID: 36457017
[TBL] [Abstract][Full Text] [Related]
12. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
13. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
14. UXT antisense RNA 1 sever as a novel prognostic long non-coding RNA in early stage pancreatic ductal adenocarcinoma patients after receiving pancreaticoduodenectomy.
Liao X; Huang R; Wang X; Huang K; Yang C; Zhou X; Han C; Su H; Ye X; Liu K; Zhu G; Peng T
J Cancer; 2021; 12(7):2122-2139. PubMed ID: 33754011
[No Abstract] [Full Text] [Related]
15. Microarray Analysis of the Expression Profile of Long Non-Coding RNAs Indicates lncRNA RP11-263F15.1 as a Biomarker for Diagnosis and Prognostic Prediction of Pancreatic Ductal Adenocarcinoma.
Huang X; Ta N; Zhang Y; Gao Y; Hu R; Deng L; Zhang B; Jiang H; Zheng J
J Cancer; 2017; 8(14):2740-2755. PubMed ID: 28928863
[TBL] [Abstract][Full Text] [Related]
16. Identification of key regulators of pancreatic cancer progression through multidimensional systems-level analysis.
Rajamani D; Bhasin MK
Genome Med; 2016 May; 8(1):38. PubMed ID: 27137215
[TBL] [Abstract][Full Text] [Related]
17. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression.
Wang WY; Hsu CC; Wang TY; Li CR; Hou YC; Chu JM; Lee CT; Liu MS; Su JJ; Jian KY; Huang SS; Jiang SS; Shan YS; Lin PW; Shen YY; Lee MT; Chan TS; Chang CC; Chen CH; Chang IS; Lee YL; Chen LT; Tsai KK
Gastroenterology; 2013 Nov; 145(5):1110-20. PubMed ID: 23896173
[TBL] [Abstract][Full Text] [Related]
18. FOLFIRINOX regulated tumor immune microenvironment to extend the survival of patients with resectable pancreatic ductal adenocarcinoma.
Wu MY; Shen M; Xu MD; Yu ZY; Tao M
Gland Surg; 2020 Dec; 9(6):2125-2135. PubMed ID: 33447563
[TBL] [Abstract][Full Text] [Related]
19. [Expression and clinical significance of Tspan 1 and Integrin α6 in human pancreatic ductal adenocarcinoma].
Shi G; Dong M; Sheng W; Zhou J; Yu D; Sun W
Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):781-6. PubMed ID: 25573220
[TBL] [Abstract][Full Text] [Related]
20. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
